Navigation Links
Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
Date:10/28/2008

ven Medimetriks management's proven abilities in building a successful business in the Dermatology and Podiatry markets."

Medimetriks President and CEO, Bradley Glassman, commented, "We are pleased to add these prescription brands to our portfolio. Perrigo is known for developing high quality products and we believe these brands will benefit both our core Dermatology and Podiatry audiences and their patients."

Centany(R) is contraindicated in individuals with a history of sensitivity reactions to any of its components. The following local adverse reactions have been reported in connection with the use of Centany(R): application site reactions and pruritus, each in 1% of patients; contact dermatitis and furunculosis, each in 0.7% of patients; and exfoliative dermatitis and rash, each in 0.3% of patients.

Please see full prescribing information.

About Medimetriks Pharmaceuticals, Inc.

Medimetriks Pharmaceuticals develops, licenses and commercializes prescription skincare products primarily for the Dermatology and Podiatry marketplaces. The Company's mission is to enhance patient quality-of-life by providing innovative therapies that advance patient care.

The Company is located at 363 Route 46 West, Fairfield, NJ 07004-2402. Please visit the Medimetriks website at http://www.medimetriks.com, call (973) 882-7512 or fax (973) 882-7502.


'/>"/>
SOURCE Medimetriks Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine news :

1. Perrigo Company To Present at the Merrill Lynch Global Pharmaceutical Conference
2. Perrigo Begins Shipments of Famotidine Complete to Customers Nationwide
3. Perrigo Company Announces Appointment of New Board Member
4. Perrigo Company to Present at The Oppenheimer & Co. Inc. 8th Annual Consumer Growth Conference
5. Perrigo Announces Approval for Rx Cetirizine Syrup
6. Perrigo Confirms Filing for Generic Version of VANOS(R)
7. Perrigo Company Announces Collaborative Agreement for Generic Topical Products With Pentech
8. Perrigo Company to Present at the Citi Investment Research Global Health Care Conference
9. Perrigo Reports Record Sales and Earnings for Third Quarter Fiscal 2008
10. Perrigo Company Announces Quarterly Dividend
11. Perrigo Receives FDA Approval to Market Orange, Coated Nicotine Gum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)PEMBROKE, Bermuda, Dec. 4 Allied World Assurance,Company Holdings, Ltd (NYSE: AWH ) today announced that Scott Carmilani,President and Chief Executive Officer, and Jack Sennott, Executive Vice,Pres
(Date:12/4/2009)SCOTTSDALE, Ariz., Dec. 4 Healthcare Trust of America, Inc. ("HTA"), a self-managed, non-traded, real estate investment trust, announced the execution of a purchase and sale agreement to acquire a th
(Date:12/4/2009)MADISON HEIGHTS, Mich., Dec. 4 The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Allergan, Inc. (NYSE: AGN ) as its February 2010 "Stock to Stud
(Date:12/4/2009)WASHINGTON, Dec. 4 While Congress debates whether health care reform would control health care costs, Leapfrog,s purchaser members point to 45 hospitals that lead through example -- delivering the be
(Date:12/4/2009)Late recurrence is a risk for some pediatric cancers, particularly Ewing sarcomas and tumors of the central nervous system, according to a new study published online December 4 in the Journal of the
Breaking Medicine News(10 mins):Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire a 92,500 Square Foot Medical Office Portfolio Located in Texas and Indiana 2Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 3
...ts act together to check the perilous trend of twi...artment has suggested a cap on the// embryo, allow...el set in motion by the Human Fertilization and Em... the wrong side of 30. Further IVF clinics w...
...be efficient on animals according to researchers a...ps we can cure HIV infection. This is our hope," s...tario. Clinical trials of the vaccine are expect...e to be careful because we have done the animal, t...
...wn the risk of Alzheimer's disease by reducing inf... recent communiqué. The finding// holds a clue as...in the 1960s and 1970s are at a lesser chance of d...ties of ceasing loss of brain cells, which is a ch...
...ged that AIDS is no more restricted to just risk g...ses are added each day according to statistics wit...bted to be AIDS positive. It is alarming to note t... too has more number of infections being spread th...
... affected only by thalassemia intermedia till Febr... positive.// Initially, blood transfusion wa...rsened, she underwent blood transfusion 10 times l...c kits from the jute baron Govind Sarda's firm; Mo...
...ed by scientists in the US attacks the malaria par...he disease that has kills one million// people a y...veloped by Walter Reed Army Institute of Research ...common, reported the science portal EurekAlert. ...
Other Medicine News:Health News:Thalassemic patient is now HIV positive due to faulty Diagnostic kit… 2
(Date:12/3/2009)NEW YORK, Dec. 3 Guidepoint Global, LLC , a leading primary research firm, today announced the launch of their Sleep Apnea Tracker, a monthly longitudinal data release that monitors and projects tre
(Date:12/3/2009)SUNNYVALE, Calif., Dec. 3 Pharmacyclics, Inc. (Nasdaq: PCYC ), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune media
(Date:12/3/2009)WILMINGTON, Del., Dec. 3 ParagonRx, a Delaware-based company specializing in pharmaceutical risk management and optimal medication use, will host a free webinar on Wednesday, Dec. 9, on the FDA,s dra
Breaking Medicine Technology:Leading Primary Research Firm Guidepoint Global Announces Launch of Sleep Apnea Tracker 2Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7 2Natural and Organic Consumers Focus on Health and Wellness Amidst Public Health Concerns 61152 1Natural and Organic Consumers Focus on Health and Wellness Amidst Public Health Concerns 61152 2K State program will give young professionals skills to protect water resources 10693 1High Altitude Mountaineer Will Cross Joins Tender 26apos 3Bs HealthiFeet Team to Raise Awareness On Foot Care for People Battling Diabetes 61149 1High Altitude Mountaineer Will Cross Joins Tender 26apos 3Bs HealthiFeet Team to Raise Awareness On Foot Care for People Battling Diabetes 61149 2High Altitude Mountaineer Will Cross Joins Tender 26apos 3Bs HealthiFeet Team to Raise Awareness On Foot Care for People Battling Diabetes 61149 3High Altitude Mountaineer Will Cross Joins Tender 26apos 3Bs HealthiFeet Team to Raise Awareness On Foot Care for People Battling Diabetes 61149 4
...Host Conference Call at 9:00 a.m. EDT-, MONTVALE,...aq: MEMY ) today announced top-line data from the...ontrolled Phase 2a study,of MEM 1003, a neuronal L...sease. The trial enrolled 183 subjects with mild t...in the United States and included monotherapy,subj...
...N.J. and NEW YORK, Oct. 12 Daiichi Sankyo,Inc. an...d today that they,have signed a contract for a co-...hi Sankyo,s AZOR(TM), a fixed combination of two,a...odipine and the,angiotensin receptor blocker, olme... letter of intent for the co-promotion agreement o...
Other Medicine Technology:Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease 2Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease 3Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease 4Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM) 2Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM) 3Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM) 4
Microalbumin Linearity Control
Total IgE Control
Lyophilized Lipid Control
High-sensitive CRP Control
Medicine Products: